MPV announces CSE’s conditional approval of its transaction with Entheon Biomedical Corp. - Seite 2
In connection with the Consolidation, post-Consolidation Resulting Issuer Shares will be sent out to registered shareholders of the Company by the Company’s transfer agent, Computershare Investor Services Inc. The Company anticipates the effective date of the Consolidation and Name Change to take place on the completion date of the Transaction.
Further Disclosure
Trading in the common shares of the Company has been halted by the CSE since July 2, 2020 following the announcement of the Amalgamation Agreement and will remain halted until the resumption of trading subsequent to obtaining final approval from the CSE.
For additional information on the Transaction, please refer to the Initial News Releases. The Company will issue further press releases regarding the Transaction as information becomes available.
About Entheon Biomedical Corp.
Entheon is a privately-held biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
For more information, please contact the Company or Entheon at:
Lesen Sie auch
MPV Exploration Inc.
Jean-Francois Perras, President and CEO
Telephone: (514) 667-7171
Entheon Biomedical Corp.
Timothy Ko, CEO and Director
Telephone: +1 (604) 562-3932
info@entheonbiomedical.com
https://entheonbiomedical.com/
Forward Looking Information
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the closing of the Transaction, the conditions to completing the Transaction, the completion of the Name Change, the completion of the Consolidation, timing and receipt of regulatory and exchange approvals, the listing of the Resulting Issuer Shares, and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. As a result, there can be no assurance that the Transaction, including the Name Change and Consolidation, will be completed as proposed or at all. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.